Ibrance
Pfizer Reports 27 Percent Oncology Growth in Q4, Touts Progress in ADC and Breast Cancer Trials
Premium
The firm recorded Q4 oncology revenues of $4.06 billion compared to $3.19 billion in the same period in 2023.
Pfizer's Breast Cancer Drug Ibrance on CMS List for Next Round of IRA Price Negotiations
Although Pfizer is not among the drugmakers suing the government to block negotiations, it has said the program will hinder drug R&D and innovation.
The model uses clinical and genomic features to predict whether patients will respond to first-line CDK4/6 and endocrine therapy.
Ibrance Plus Frontline Standard Therapy Delays Progression in HER2, HR-Positive Breast Cancer
Premium
Pfizer will discuss the data on its CDK4/6 inhibitor plus anti-HER2 and endocrine therapy with regulators, hoping it will become a new standard option.
Pfizer's oncology revenues jumped 30 percent in the third quarter, with growth from several precision oncology drugs.